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Summary 
Background and objectives: Soluble TWEAK (sTWEAK) concentrations 
have been associated with the presence of chronic kidney disease (CKD) 
and cardiovascular disease (CVD). Now, we hypothesized that sTWEAK 
levels may relate to the increased prevalence of atherosclerotic plaques, 
vascular calcification and cardiovascular outcomes observed in patients 
with CKD. 
Design, setting, participants and measurements: A multicenter cross-
sectional study was conducted in 1058 patients with CKD stages III-VD 
(mean age, 58±13, 665 men) but without any history of CVD from the 
NEFRONA study (a study design to assess the prevalence of surrogate 
markers of CVD). Ankle-brachial index (ABI) and B mode ultrasound was 
performed to detect the presence of carotid and/or femoral atherosclerotic 
plaques, together with biochemical measurements and sTWEAK 
assessment. Patients were followed for cardiovascular outcomes (follow-
up period of 3.13±1.15 years). 
Results: sTWEAK serum levels were reduced in parallel with a reduction 
in estimated glomerular filtration rate. sTWEAK concentrations were 
independently and negatively associated with carotid intima/media 
thickness. Moreover, sTWEAK levels were reduced in patients with 
carotid atherosclerotic plaques but not in those with femoral plaques. 
After adjustment by confounders, the OR for presenting carotid 
atherosclerotic plaques in patients in lower vs higher tertile of sTWEAK 
was 3.80 [2.36-5.15 (IQR); p<0.001]. Furthermore, sTWEAK levels were 
reduced in patients with calcified carotid atherosclerotic plaques. The OR 
for presenting calcified carotid plaques was 2.48 (1.51-4.07; p<0.001) 
after multivariable adjustment. Finally, after the follow-up, 41 fatal and 68 
nonfatal cardiovascular events occurred. In a Cox model after controlling 
for potential confounding factors, patients in the lower tertile of sTWEAK 
concentrations had an increased risk of fatal and nonfatal cardiovascular 
events [HR: 2.64 (1.48-4.68); p<0.005] and cardiovascular mortality [HR: 
3.06 (1.14-8.238); p<0.05]. 
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Conclusions: Diminished sTWEAK levels are associated with the 
presence of carotid atherosclerotic plaques in CKD patients. Additionally, 
sTWEAK impacted the predictability of cardiovascular morbi-mortality.
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Introduction 
Chronic kidney disease has become recognized as a key 
independent factor for several health outcomes including cardiovascular 
disease (CVD) (1). In fact, compared to the age adjusted CVD mortality in 
the general population, CKD patients die at accelerated rate, 15 to 30 
times higher than non-CKD subjects (2). The mechanisms for the 
elevated CVD risk in CKD patients are complex and may implicate 
changes in both the vasculature and heart. Most cardiovascular  (CV) 
events  appear to be from sudden deaths related to possible heart failure 
or arrhythmias (3-4). In addition, the presence of accelerated 
atherosclerosis in CKD could play a role in the higher cardiovascular 
mortality. Atherosclerosis is a multifactorial disease characterized by 
chronic inflammation and excessive cell proliferation. In vivo and in vitro 
studies have elucidated molecular and cellular pathways of inflammation 
that promote atherosclerosis. Unveiling the role of several cytokines as 
inflammatory messengers provided a potential mechanism whereby risk 
factors for atherosclerosis can alter arterial wall, and produce a systemic 
response that favors atherothrombotic events (5). Of these, tumor 
necrosis factor-like weak inducer of apoptosis (TWEAK) is a type II 
transmembrame glycoprotein that participates, through its sole receptor 
fibroblast growth factor inducible 14 (Fn14), in several cellular responses 
associated with atherosclerosis (6). In fact, different experimental studies 
have demonstrated a key role of TWEAK/Fn14 axis in atherosclerotic 
plaque development, progression and rupture (7-9). In addition, specific 
gain or loss-of-function phenotypes have demonstrated the role of 
TWEAK and Fn14 in the development of abdominal aortic aneurysms, 
stroke, myocardial infarction and heart failure, among others (10-13). 
As other member of the TNF superfamily, TWEAK can be 
proteolytically processed by furin, leading to the release of an 18 kDa 
soluble form (sTWEAK) (14). The use of sTWEAK as a potential 
biomarker of atherosclerosis was described in 2007, analyzing the 
secretome from human carotid atherosclerotic plaques (15). We 
demonstrated that sTWEAK is secreted in lower amount from human 
carotid atherosclerotic plaques than in healthy arteries (15).  After that, 
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the association of sTWEAK with CVD or CVD-related diseases has been 
extensively studied. Thus, sTWEAK concentrations are diminished in 
subjects with coronary artery disease (16), abdominal aortic aneurysm 
(17), systolic heart failure (18), type II diabetes (19) and CKD (20). The 
pathological effects observed in different animals model induced by 
TWEAK are mediated by binding to its receptor Fn14. Fn14 is almost 
absent in healthy tissues but is highly upregulated in human 
atherosclerotic plaques (21). Binding of sTWEAK with Fn14 in 
pathological tissues could be responsible to the reduction observed in 
CKD patients with vascular affectations.  
The NEFRONA study was an observational multicenter prospective 
study designed to evaluate the prevalence and evolution of subclinical 
atheromatosis in CKD patients, as well as the contribution of vascular 
imaging for a more precise cardiovascular risk assessment (22). The 
aims of the study are multiple: first, we wanted to confirm and extend the 
usefulness of sTWEAK as a biomarker of the presence of atherosclerotic 
plaques in CKD patients. Second, we wanted to test the ability of 
circulating sTWEAK concentrations to predict vascular calcification. 
Finally, we wanted to know the impact of sTWEAK on cardiovascular 
outcomes in the NEFRONA population. 
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Materials and Methods 
Subjects 
NEFRONA study is a 4-year prospective multicenter cohort study 
aimed to assess the predictive value of non-invasive techniques for CVD 
events and mortality in patients with CKD (22). In that study, 2445 CKD 
subjects (18 and 74 years of age were eligible if they had CKD stage 3 or 
higher as defined by current guidelines (eGFR lower than 
60 mL/min/1.73 m2 estimated using the 4-variable Modification of Diet in 
Renal Disease (MDRD) equation) were enrolled from October 2010 to 
June 2012. Five hundred and fifty nine control subjects with and MDRD 
over 60 ml/min/1.73 m2 were also recruited. 
One thousand and fifty eight subjects from the NEFRONA study 
with available serum sample were included in the study. Subjects were 
enrolled within 69 Spanish primary care centres distributed in 38 different 
regions from Spain. The exclusion criteria were previous CV events, 
active infections (HIV, tuberculosis), pregnancy, having received any 
organ transplantation, and having a life expectancy of <1 year. Each local 
ethics committee approved the study, and subjects were included after 
providing informed consent. 
 
Clinical and biochemical data 
At recruitment, the subjects were asked to complete a questionnaire 
including clinical history of diabetes, hypertension and dyslipidemia; CV 
risk factors (such as smoking habit) and medication use. 
The ultrasound explorations (carotid and femoral) were performed 
according to a standardized protocol by three itinerant teams belonging to 
the UDETMA (Unit for Detection and Treatment of Atherothrombotic 
Diseases, Hospital Universitari Arnau de Vilanova, Lleida, Spain). The 
itinerant teams also collected the anthropometric parameters as well as 
blood samples. Blood samples were processed immediately after 
extraction and storage at -20º C. After that, samples were sent and stored 
within 24 h at the centralized biobank of the Spanish Network for 
Nephrological Research (REDinRen).  
Biochemical parameters were obtained from a routine fasting blood 
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test. Serum concentrations of sTWEAK were determined in duplicate with 
commercially available ELISA kits (Bender MedSystems, Vienna, 
Austria). The minimum detectable level of sTWEAK was 10 pg/ml. Intra- 
and interassay coefficients of variation were 7.3 and 8.5%, respectively. 
 
Carotid and femoral ultrasound 
B-mode ultrasound of the carotid and femoral arteries was 
performed using the Vivid BT09 apparatus (General Electric instrument) 
equipped with a 6-13 MHz broadband linear array probe. The analysis of 
the presence of atheromatous plaques was performed by a single reader 
in a blinded fashion, using the semi-automatic software EchoPAC 
Dimension (General Electric Healthcare). To assess the quality of the 
reading and the intraobserver reliability, a sample of 20 individuals was 
measured 3–5 times on different days. A kappa coefficient of 1 was 
obtained, indicating excellent intraobserver reliability. 
Ultrasound imaging was performed for both carotid arteries with the 
subjects in a supine position and the head turned 45° contralateral to the 
side of the probe. The presence of atheromatous plaques at each site 
was defined as carotid intima-media thickness (cIMT) ≥1.5 mm protruding 
into the lumen, which is the criterion given in the ASE Consensus 
Statement (23) and the Mannheim CIMT Consensus (24). This criterion 
was used in the ARIC study (25) and in the Framingham Offspring Study 
(26), two important Studies showing the predictive value of atheromatous 
plaques in CV risk. 
B-mode ultrasound imaging was performed in the right and left 
femoral arteries. Subjects were examined in a supine position, and the 
presence of atheromatous plaques was explored in the common and 
superficial femoral arteries. 
 
Statistical Analyses 
All of the statistical analyses were performed using the SPSS 11.0 
(SPSS, Chicago, IL) statistical package. Non-normally distributed 
variables were expressed as median (range), and normally distributed 
variables were expressed as mean±SD. Between-group comparisons 
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were assessed for nominal variables with the X2 test and by Kruskal-
Wallis test (ANOVA). Spearman’s rank correlation was used to determine 
correlations between variables. Stepwise multivariate regression analysis 
was used to assess the predictors for ABI and c-IMT levels. Time-to-
event analysis of cardiovascular outcomes was done using the Cox 
proportional hazards model, including adjustment for potential 
confounding factors. Data are presented in the form of hazard ratios and 
95% confidence intervals. 
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Results 
Soluble TWEAK concentrations in CKD patients 
The demographic and clinical characteristics of the studied 
population are summarized in Table 1. There were significant differences 
among the different CKD stages with regard to age, gender, body mass 
index and cardiovascular risk factors. Confirming previous data in smaller 
populations, across increasing CDK stages, gradual decreases in 
sTWEAK concentrations were observed (Fig. 1A, p<0.001). The lowest 
sTWEAK level was found in patients undergoing dialysis (Table 1). No 
difference in sTWEAK concentrations was observed in CKD patients with 
diabetes, hypertension or dyslipemia compared with those without these 
cardiovascular risk factors. However, current smokers (N=605) presented 
a small reduction in sTWEAK concentrations [372 (246-557) vs 412 (267-
595) pg/mL; p<0.05]. No differences were found according to the 
prescription of anti-hypertensive drugs, statins or anti-diabetic treatments. 
Univariate associates of ABI and IMT are given in Table 2.  ABI was 
negatively associated with eGFR, c-IMT, total cholesterol, LDL-c, and 
glucose concentrations. In addition, c-IMT was positively associated with 
age, BMI, SBP, eGFR, triglycerides, glucose and hs-CRP concentrations, 
and negatively correlated with DBP, HDL-c, ABI and sTWEAK levels. To 
clarify whether sTWEAK is an independent predictor of c-IMT in the 
population studied, multiple regression analysis was performed. Variables 
included in the analysis were age, gender, SBP, DBP, cholesterol, LDL-c, 
HDL-c, triglycerides, glucose, eGFR and hs-PCR levels as well as 
sTWEAK concentrations were included in the model. In such model, age 
(β=0.478; p<0.001), gender (men/women; β=-0.100; p<0.01), HDL-c (β=-
0.095; p<0.01), glucose (β=0.064; p<0.05), eGFR (β=0.118; p<0.001), 
SBP (β=0.068; p<0.05), as well as sTWEAK (β=-0.110; p<0.001) were 
independently associated with c-IMT. 
 
sTWEAK as a predictor of carotid atherosclerotic plaques 
Subjects with atherosclerotic plaques (N=729) showed a reduction 
in sTWEAK concentrations compared with those without atherosclerotic 
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plaques (N=329) [357 (244-517) vs 490 (296-652) pg/mL; median (IQR); 
p<0.001]. When we analyzed sTWEAK serum levels according with the 
vascular territory affected (femoral or carotid arteries), only patients with 
carotid or both carotid and femoral plaques showed lower sTWEAK levels 
compared with those without atherosclerotic plaques (Fig. 1B). The 
presence of femoral atherosclerotic plaques did not modify sTWEAK 
concentrations in our patient population (Fig. 1B). Multivariable logistic 
regression analysis including age, gender, BMI, smoker status, 
cardiovascular factors, cardiovascular treatments, eGFR and hs-PCR 
concentrations as well as sTWEAK levels was performed to assess 
predictors of the presence or absence of carotid atherosclerotic plaques 
in our studied population. Of these variables, age, current smokers, 
eGFR, and low sTWEAK levels were independent predictors for the 
presence of carotid atherosclerotic plaques (Table 3). In addition, we 
analyzed sTWEAK serum levels according with the presence of calcified 
carotid plaques. Patients with calcified carotid atherosclerotic plaques 
showed a reduction in sTWEAK levels (Fig. 1C) compared to patients in 
which the plaques were not calcified. After multivariable logistic analysis, 
age, eGFR, hs-CRP>3 mg/L and low sTWEAK concentrations were 
independent predictors for the presence of calcified carotid 
atherosclerotic plaques (Table 3). 
 
 
sTWEAK and cardiovascular outcomes  
Cardiovascular outcomes were determined from the day of 
examination onward, with a mean of follow-up period of 3.13±1.15 years. 
Eighty-nine patients died, 41 (46%) of which were due to CVD-related 
disease such as myocardial infarction (N=11), thrombotic stroke (N=6), 
sudden death (N=12), mesenteric infarction (N=7), or other CVD-related 
causes (N=5). sTWEAK levels was reduced in patients suffering a fatal 
CV event compared with those free for fatal CV event [231 (174-354) vs 
395 (261-577) pg/mL; median (IQR); p<0.001]. Kaplan-Meier curves 
showed a significant association of lowest sTWEAK concentrations with 
worse survival (Log-Rank=15.6; p<0.001; Fig. 2A). In univariate Cox 
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analysis, the predictors for time-to-cardiovascular death were presence of 
diabetes, eGFR and low sTWEAK concentrations (Table 4). Multivariate 
Cox was used to study the impact of these variables considering 
additional adjustment for age, gender, eGFR, smoker status, 
cardiovascular risk factors, hs-CRP and sTWEAK levels. In this first 
model, presence of diabetes, eGFR and low sTWEAK concentrations 
persisted as predictors of cardiovascular death (Table 4). In addition, in a 
second model after adjustment for cardiovascular treatments, only eGFR 
and low TWEAK levels persisted as independent predictors of 
cardiovascular death (Table 4).  
The same analysis was done for total mortality.  Crude analysis 
showed that age, presence of diabetes, eGFR and low sTWEAK were 
predictors of total mortality. After adjustment for age, gender, eGFR, 
smoker status, cardiovascular risk factors, hs-CRP and sTWEAK levels, 
only age, presence of diabetes and eGFR levels persisted as predictors 
of total mortality (Table 4). Similar results were obtained after inclusion of 
cardiovascular treatments in the adjusted model (Table 4). 
Due to the limited number of fatal cardiovascular events registered, 
we also analyzed the impact of sTWEAK concentrations on the prediction 
of CV event for a composite of fatal and nonfatal CV event (n=109). 
During the follow-up period, 68 addition nonfatal cardiovascular events 
were registered as follow: transient ischemic attack (N=4), unstable 
angina (N=16), myocardial infarction (N=12), intermittent claudication 
(N=11), aortic aneurysm (N=2), stroke (N=16), and others CV event 
(N=7). sTWEAK concentrations were reduced in CKD patients suffering a 
non-fatal CV event compared with those without CV event [275 (191-428) 
vs 403 (263-586) pg/mL; median (IQR); p<0.001]. The figure 2B displays 
the estimated cumulative evidence of major CV event. When CKD 
patients were grouped according to sTWEAK levels tertiles, the 
probability of developing a CV event increased in the lowest tertile of 
sTWEAK concentrations group [HR= 3.74 (95% CI, 2.18 to 6.42); 
p<0.001]. Cox-proportional Hazards model was performed to study the 
impact of traditional confounding factors on the probability of developing a 
CV event. The first model included age, gender, smoker status, traditional 
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cardiovascular risk factors, eGFR, and hs-CRP levels as well as sTWEAK 
concentrations. After adjustment, eGFR, hs-CRP levels >3mg/L and low 
sTWEAK levels were associated with an increase in the risk of 
developing a CV event (Table 4). These associations persisted in a 
second model including cardiovascular treatments (Table 4).  
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Discussion 
In this work, we investigated sTWEAK serum levels as predictors of 
cardiovascular outcomes in a CKD population with or without 
cardiovascular risk factors but without any history of CVD. This population 
included CKD patients from several primary care centers in a daily clinical 
practice, with or without concomitant medication, with the aim to have a 
representative Spanish population. sTWEAK was originally identified as a 
soluble protein that was secreted in lower amounts from atherosclerotic 
plaques than from healthy arteries (16). Previously (20) and in this study, 
the decline in eGFR was related with a gradual diminution in sTWEAK 
concentrations. In addition, sTWEAK was also negatively and 
independently associated with c-IMT. This data are in agreement with 
previous studies in which sTWEAK was negatively associated with c-IMT 
in asymptomatic subjects (16) or in non-dialysis CKD patients (27-28). 
However, the association between c-IMT and sTWEAK was lost and, 
indeed, positive association has been reported (29). These contradictory 
data could be due to the presence of different therapy regimens used in 
those patients (30) and to the high inter-operator variability of the 
ultrasound technique.  
An important finding from our study is the difference of sTWEAK 
concentrations observed depending on the vascular territory affected. 
Thus, sTWEAK was reduced in CKD patients with carotid plaques 
compared with those with femoral atherosclerotic plaques or without 
plaques. In addition, in a multivariable logistic regression analysis, only 
age, smoking, eGFR and sTWEAK concentrations were independent 
predictors for the presence of carotid atherosclerotic plaques. These 
results are in agreement with previous data from subjects free for clinical 
cardiovascular disease (30). Femoral plaques have an increment in their 
fibrotic content compared with carotid atherosclerotic plaques. In addition, 
carotid plaque are characterized by a more inflammatory cell content that 
femoral arteries (31). Differences in sTWEAK concentrations between 
carotid and femoral plaque could be related to differences in cellular 
composition. More importantly, sTWEAK was also related to the presence 
of vascular calcification. Vascular calcification is a highly prevalent 
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phenotype that is identified frequently in patients with CKD (32). In 
addition, vascular calcification is both a risk factor and contributor to 
morbidity and mortality in CKD patients (33). In this sense, sTWEAK was 
and independent predictor of both cardiovascular mortality and first 
cardiovascular events in our studied population. These data are 
consistent with previous survival data from patients with stable heart 
failure (34) and cardiovascular outcomes in non-dialysis CKD (35). 
Interestingly, we have observed that sTWEAK was not associated with 
total mortality. This data could indicate that sTWEAK is a good biomarker 
for cardiovascular prognosis but not for other pathologies.  
Strengths of this study are the large sample size of CKD patients 
included in our study, and the fact that the vascular exploration was 
performed by the same itinerant team and evaluated by a single reader, 
minimizing the variability associated with the technique. Furthermore, the 
assessment of plaque presence also in the femoral territories adds 
additional information to the analysis. In addition, this is the first time that 
sTWEAK levels are associated with the presence of cardiovascular 
events and cardiovascular mortality in a general CKD population. 
However, some limitations of our study should be highlighted for a correct 
interpretation of the implications of our findings. There is an intentional 
bias, because only patients with no history of cardiovascular events were 
included, as the study was aimed to primary prevention of cardiovascular 
events. This bias was necessary, but its consequences have to be 
considered when interpreting the results. A relatively low number of 
cardiovascular deaths were reported during the follow-up, which might 
limit the statistical power of our analysis.  
We have analyzed sTWEAK serum levels and different 
concentrations of this protein have been published depending of the 
source analyzed (plasma, serum or urine) (36). Reagents to measure 
sTWEAK concentrations are commercially available for research 
purposes only. We need a standardization of the available kits to obtain 
consensual normal ranges of sTWEAK levels (36).  Finally, in a very 
complex disease such as CVD, a single biomarker could be not sufficient 
to detect unstable atherosclerotic plaques. sTWEAK levels could add 
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information to know cardiovascular risk factors and contribute to a better 
prediction of cardiovascular events. 
In conclusion, reduced sTWEAK serum levels are associated with 
the presence of carotid atherosclerotic plaques in CKD patients. In 
addition, sTWEAK levels were significantly and independently related 
with cardiovascular outcomes in CKD patients. 
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Figure Legends 
Figure 1: sTWEK levels, atherosclerotic burden and vascular 
calcification in CKD patients without any history of CVD. 
A) Box plots showing the reduction in sTWEAK serum concentrations 
[median (IQR)] in parallel with the reduction in eGFR. * p<0.001 vs CKD 
III; † p<0.001 vs CKD IV-V. 
B) Box plots showing sTWEAK levels [median (IQR)] according to the 
vascular territory affected. No plaques, N=329; Carotid plaques, N=193; 
Femoral plaques, N=116; Both, N=420. *p < 0.001 vs no plaques. 
C) Blox plots showing sTWEAK levels [median (IQR)] according to the 
presence of calcified carotid atherosclerotic plaque. No, N=900; Calcified 
carotid plaques; N=158. 
 
Figure 2: Impact of sTWEAK in cardiovascular outcomes 
A) Kaplan-Meier curve of cardiovascular mortality risk in CKD patients 
according with their sTWEAK levels.  
B) Kaplan-Meier plot of cumulative probability of a first major CV event 
when CKD patients were grouped according to their sTWEAK 
concentration tertiles. 
Low sTWEAK levels were defined as sTWEAK concentration below the 
33rd percentile (<289 pg/mL) and high sTWEAK as its concentration 
above the 66th percentile (>465 pg/mL). 
Table 1.- Baseline demographic and biochemical parameters. 
 All patients 
(N=1058) 
CKD III  
(N=435) 
CKD IV-V  
(N=377) 
CKD 5D  
(N=246) 
p 
Age, years 58±13 61±11 58±12 53±14 <0.001 
Male, % (N) 62.8 (665) 70.8 58.9 54.9 <0.001 
BMI, Kg/m2 28 (25-32) 29 (26-32) 28 (25-32) 27 (23-32) <0.001 
SBP, mmHg 140 (129-156) 142 (130-156) 143 (130-159) 137 (123-153) <0.001 
DBP, mmHg 81 (75-89) 81 (75-89) 81 (74-88) 80 (70-90) 0.102 
Cholesterol, mg/dL 178±40 187±37 177±38 163±42 <0.001 
LDL-cholesterol, mg/dL 101±34 110±32 100±34 87±32 <0.001 
HDL-cholesterol, mg/dL 46 (38-57) 47 (39-56) 47 (37-59) 44 (36-54) <0.05 
Triglycerides, mg/dL 126 (92-177) 125 (96-175) 127 (92-185) 124 (82-176) 0.814 
Glucose, mg/dL 99 (88-118) 103 (92-125) 98 (89-112) 91 (82-113) <0.001 
Hs-CRP, mg/L 1.88 (0.92-4.7) 1.83 (0.92-4.07) 1.68 (0.82-4.22) 2.44 (1.14-7.16) <0.005 
eGFR, mL/min/1.73 m2 26 (12-40) 43 (36-50) 21 (15-25) 6.6 (5.2-9.1) <0.001 
ABI 1.04 (0.95-1.15) 1.00 (0.93-1.12) 1.04 (0.95-1.15) 1.07 (0.96-1.25) <0.001 
c-IMT, mm 0.71 (0.62-0.82) 0.75 (0.66-0.84) 0.68 (0.59-0.81) 0.69 (0.60-0.79) <0.001 
Smoker, % (N) 57.2 (605) 60.9 (265) 55.7 (210) 52.8 (130) 0.095 
Dyslipemia, % (N) 
       Medical Treatment, % (N) 
64.6 (684) 
57.0 (603) 
71.7 (312) 
57.7 (251) 
69.0 (260) 
67.1 (253) 
45.5 (112) 
40.2 (99) 
<0.001 
Diabetes Mellitus, % (N) 
       Medical Treatment, % (N) 
29.0 (307) 
27.9 (295) 
32.2 (140) 
31.9 (139) 
30.0 (113) 
28.6 (108) 
22.0 (54) 
19.5 (48) 
<0.05 
Hypertension, % (N) 
       Medical Treatment, % (N) 
92.1 (974) 
89.2 (944) 
91.5 (398) 
92.6 (403) 
96.0 (362) 
95.8 (361) 
87.0 (214) 
73.2 (180) 
<0.001 
Familial CVD, % (N) 8.5 (90) 9.4 (41) 9.0 (34) 6.1 (15) 0.296 
sTWEAK, pg/mL 389 (254-576) 459 (323-631) 405 (286-549) 214 (115-346) <0.001 
Results expressed as media ± SD or median (IQR). BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood 
pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; hs-CRP: high-sensitivity C reactive protein; eGFR: 
estimated glomerular filtration rate; ABI: Anklebrachial index; c-IMT: carotid intima/media thickness. 
Table 2.- Spearman correlations coefficients between c-IMT, ABI, sTWEAK levels, and selected parameters in asymptomatic 
subjects. 
 
 
 c-IMT ABI sTWEAK 
 r p r p r p 
Age, years 0.54 <0.001 -0.03 0.33 -0.02 0.43 
BMI, kg/m2 0.21 <0.001 -0.05 0.07 0.03 0.29 
SBP, mm Hg 0.18 <0.001 -0.00 0.96 -0.03 0.26 
DBP, mm Hg -0.07 <0.05 0.03 0.39 -0.04 0.17 
Cholesterol, mg/dL -0.02 0.64 -0.14 <0.001 0.13 <0.001 
HDL-c, mg/dL -0.12 <0.001 -0.06 0.06 0.10 <0.01 
LDL-c, mg/dL 0.09 0.14 -0.15 <0.001 0.15 <0.001 
Triglicerydes, mg/dL 0.07 <0.05 -0.05 0.14 -0.08 <0.05 
Glucose, mg/dL 0.22 <0.001 -0.11 <0.001 0.01 0.88 
Hs-CRP, mg/L 0.13 <0.001 -0.04 0.21 -0.04 0.23 
eGFR, mL/min/1.73m2 0.22 <0.001 -0.15 <0.001 0.35 <0.001 
c-IMT, mm -------- -------- -0.12 <0.001 -0.10 <0.01 
ABI -0.18 <0.001 -------- -------- -0.05 0.08 
sTWEAK, pg/mL -0.10 <0.01 -0.05 0.08 -------- -------- 
 
 
BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-
density lipoprotein; eGFR: estimated glomerular filtration rate; hs-CRP: high-sensitivity C-reactive protein; ABI: Ankle-brachial 
index; c-IMT: carotid intima/media thickness. 
 
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Table 3.- Multivariate logistic analysis of modeling the  presence of carotid or calcified carotid atherosclerotic plaques in the 
studied population. 
 
 Odds Ratio Confidence Interval (95%) p 
Carotid Plaques    
Age, years 1.11 1.09-1.12 <0.001 
Current Smoker, yes vs no 2.02 1.44-2.82 <0.001 
eGFR, mL/min/1.73m2 0.99 0.98-0.99 <0.05 
sTWEAK, lower vs higher tertile 3.48 2.35-5.15 <0.001 
    
Calcified Carotid Plaques    
Age, years 1.07 1.05-1.091 <0.001 
eGFR, mL/min/1.73m2 0.98 0.97-0.99 <0.01 
Hs-CRP, >3 mg/L 1.64 1.14-2.36 <0.05 
sTWEAK, lower vs higher tertile 2.48 1.51-4.07 <0.001 
 
The analysis included age, gender, smoker status, cardiovascular risk factors, cardiovascular treatments, eGFR and hs-CRP 
levels as well as sTWEAK concentrations.  
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Con formato: Inglés (Estados Unidos)
Table 4.- Univariate and multivariate COX regression analysis predicting for cardiovascular outcomes and mortality. 
 
 Cardiovascular Mortality 
 Crude Model 1 Model 2 
Diabetes, yes vs no 2.08 (1.39-4.73) <0.005 2.52 (1.28-4.96) <0.01 2.08 (0.61-7.12) 0.242 
eGFR, mL/min/1.73m2 0.94 (0.92-0.97) <0.001 0.95 (0.93-0.98) <0.001 0.95 (0.93-0.98) <0.001 
sTWEAK, lower vs higher tertile 4.92 (2.03-11.88) <0.001 3.24 (1.21-8.69) <0.05 3.06 (1.14-8.24) <0.05 
  
 Total Mortality 
 Crude Model 1 Model 2 
Age, years 1.03 (1.01-1.06) <0.005 1.04 (1.02-1.06) <0.001 1.04 (1.02-1.06) <0.001 
Diabetes, yes vs no 1.82 (1.19-2.77) <0.01 1.87 (1.19-2.95) <0.01 2.43 (1.09-5.39) <0.05 
eGFR, mL/min/1.73m2 0.96 (0.94-0.97) <0.001 0.96 (0.94-0.97) <0.001 0.96 (0.94-0.98) <0.001 
sTWEAK, lower vs higher tertile 2.12 (1.28-3.50) <0.005 1.23 (0.72-2.11) 0.449 1.20 (0.70-2.06) 0.500 
  
 Fatal and Non Fatal Cardiovascular Events 
 Crude Model 1 Model 2 
Age, years 1.03 (1.01-1.04) <0.005 1.02 (1.01-1.04) <0.05 1.02 (1.00-1.04) <0.05 
Diabetes, yes vs no 2.46 (1.69-3.58) <0.001 2.30 (1.54-3.43) <0.001 3.00 (1.48-6.06) <0.001 
eGFR, mL/min/1.73m2 0.97 (0.96-0.99) <0.001 0.97 (0.96-0.99) <0.001 0.97 (0.96-0.99) <0.005 
sTWEAK, lower vs higher tertile 3.74 (2.17-6.42) <0.001 2.63 (1.48-4.68) <0.001 2.64 (1.48-4.68) <0.005 
 
The first model included age, gender, smoker status, cardiovascular risk factors, eGFR and hs-CRP levels as well as sTWEAK 
concentrations. The second model also included cardiovascular treatments. 
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